Iqbal A et al. Indacaterol once-daily improves dyspnoea in COPD patients: a 26-week placebo-controlled study with open-label tiotropium comparison.
Mahler DA, Palange P, Iqbal A et al. Indacaterol once-daily improves dyspnoea in COPD patients: a 26-week placebo-controlled study with open-label tiotropium comparison. ❋ Unknown (2009)
Involving some 5993 subjects, the trial authors concluded that there were tiotropium related improvements in lung function and quality of life and fewer exacerbations. ❋ James Gaulte (2009)
The editorial was a commentary in part on the publication of the results of the large,multi- center, UPLIFT trial which examined the effects of tiotropium on several outcomes in patients with COPD whose FEV1 values were 70% or less of predicted. ❋ James Gaulte (2009)
GOLD 's position is that there is no definitive evidence indicating if a LABA is better or worse than an anticholinergic and with the continuing controversy over the safety of LABAs many doctors may well choose to begin with an anticholenergic particularly since there is now one that is long acting (once a day use), i.e. tiotropium (Spiriva). ❋ James Gaulte (2006)
Four studies would compare improvements in lung function in patients treated with the combination, its components, tiotropium or placebo.
Roflumilast also demonstrated a statistically significant improvement compared to placebo on lung function, in two supportive studies over a six-month period when added to the long-acting bronchodilators, tiotropium or salmeterol. ❋ Unknown (2010)
A LABA/ICS combination should also be used, but tiotropium will not be of benefit. ❋ Unknown (2010)
Additionally, among the three agents in development within the novel LABA/long-acting muscarinic antagonist (LAMA) drug class, surveyed pulmonologists and PCPs view Boehringer Ingelheim's olodaterol/tiotropium combination to be the most promising. ❋ Unknown (2010)
Spiriva® HandiHaler® (tiotropium bromide inhalation powder) is a registered trademark of ❋ Unknown (2010)
Secondly, theres a reduced mortality rate for treatment with tiotropium, that was not known and thats very important as well. ❋ Unknown (2010)
On the contrary, the time to first exacerbation was significantly longer in patients receiving tiotropium bromide Spiriva when compared with placebo! ❋ Unknown (2010)
Professor of Medicine, Catholic University Leuven in Belgium discusses the safety aspects shown in the UPLIFT trial for Boehringer Ingelheims Spiriva (tiotropium) for the treatment of ❋ Unknown (2010)
The tablet is expected to be launched soon, starting in Germany and the UK and will compete with Boehringer Ingelheim/Pfizer's Spiriva (tiotropium), ❋ Unknown (2010)
